好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2018 Annual Meeting | N1 - Neuroscience in the Clinic: Autism Myth Busters

Sunday 04/22/18
03:30 PM - 05:30 PM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Neuroscience in the Clinic Session
Shafali Jeste, MD, FAAN, Sarah J. Spence, MD, PhD
Child Neurology and Developmental Neurology
Participants should become familiar with insights on early signs of ASD gained from studies of infants at risk for ASD; the definition of a biomarker and an understanding of the types of biomarkers investigated in ASD; challenges around clinical trial design and implementation in ASD; evidence around pharmacological interventions for ASD and updates from clinical drug trials; and updates on autism genetics, from recommended diagnostic practices to implications for management.
2.00 CME credits
Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement
Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider
Case-based, Didactic, Interactive, Audience Participation
Event Timeline
03:30 PM - 03:45 PM Speaker Clinical Vignette: Autism Spectrum Disorders
Sarah J. Spence, MD, PhD
03:30 PM - 05:30 PM Abstract 001 - The Broader Autism Phenotype in Tuberous Sclerosis Complex
Jamie K. Capal, MD
03:30 PM - 05:30 PM Abstract 002 - Sulforaphane Treatment of Children with Autism Spectrum Disorder (ASD) – A Progress Report
Andrew W. Zimmerman, MD, FAAN
03:30 PM - 05:30 PM Abstract 003 - Multi-Gene Panels vs. Diagnostic Exome Sequencing: A Comparison of Genetic Testing Options for Neurodevelopmental Disorders
Jing Wang, MD
03:45 PM - 04:00 PM Speaker Biomarkers of ASD: From Screening to Clinical Stratification to Quantitative Outcomes
Shafali Jeste, MD, FAAN
04:00 PM - 04:10 PM Speaker N1.001: The Broader Autism Phenotype in Tuberous Sclerosis Complex
Jamie K. Capal, MD
04:10 PM - 04:25 PM Speaker Clinical Trials and Treatments in ASD: What Works and Why Trials Fail
04:25 PM - 04:35 PM Speaker N1.002: Sulforaphane Treatment of Children with Autism Spectrum Disorder (ASD) – A Progress Report
Andrew W. Zimmerman, MD, FAAN
04:35 PM - 04:50 PM Speaker Updates in Autism Genetics: Clinical and Scientific Implications for Precision Medicine
Daniel H. Geschwind, MD, PhD
04:50 PM - 05:00 PM Speaker N1.003: Multi-Gene Panels vs. Diagnostic Exome Sequencing: A Comparison of Genetic Testing Options for Neurodevelopmental Disorders
Jing Wang, MD
05:00 PM - 05:30 PM Q&A Panel Discussion
Faculty Disclosures
Shafali Jeste, MD, FAAN Dr. Jeste has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche Pharmaceuticals. Dr. Jeste has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Pharmaceuticals. Dr. Jeste has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis Pharmaceuticals. Dr. Jeste has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN Continuum. The institution of Dr. Jeste has received research support from NIH. The institution of Dr. Jeste has received research support from DoD. The institution of Dr. Jeste has received research support from Dup15q Alliance.
Sarah J. Spence, MD, PhD Dr. Spence has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for dup15qalliance. The institution of Dr. Spence has received research support from Hoffman La Roche. The institution of Dr. Spence has received research support from NIH.
No disclosure on file
Jamie K. Capal, MD Dr. Capal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CTI Clinical Trials. Dr. Capal has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Intellectual Disability Research. The institution of Dr. Capal has received research support from NIH. The institution of Dr. Capal has received research support from Roche . The institution of Dr. Capal has received research support from Ionis.
Andrew W. Zimmerman, MD, FAAN No disclosure on file
Jing Wang, MD No disclosure on file
Daniel H. Geschwind, MD, PhD Dr. Geschwind has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Ovid Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for AcuraStem, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axial Biotherapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Falcon Computing. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier-Biological Psychiatry. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NYAS. Dr. Geschwind has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Covington& Burling LLP. Dr. Geschwind has stock in none related to talk. The institution of Dr. Geschwind has received research support from CurePSP. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from Rainwater Charitable Foundation. The institution of Dr. Geschwind has received research support from NIMH. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from NIH. The institution of Dr. Geschwind has received research support from The Simons Foundation. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from NIMH. The institution of Dr. Geschwind has received research support from NINDS/NIA. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from NIH/NINDS. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from U of Virginia and NIH/NIMH. The institution of Dr. Geschwind has received research support from NIH. The institution of Dr. Geschwind has received research support from NIH/NHGRI. The institution of Dr. Geschwind has received research support from NIH/NIMH. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care.
Heather Newman No disclosure on file
Susan L. Connors, MD No disclosure on file
Darcy Krueger, MD Dr. Krueger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NobelPharma USA. Dr. Krueger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for RegenxBio. Dr. Krueger has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis Pharmaceuticals. Dr. Krueger has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Greenwich Biosciences. The institution of Dr. Krueger has received research support from Greenwich Bioscience. The institution of Dr. Krueger has received research support from Marinus Pharmaceuticals. The institution of Dr. Krueger has received research support from National Institutes of Health. The institution of Dr. Krueger has received research support from Food and Drug Administration. The institution of Dr. Krueger has received research support from TSC Alliance.
Mustafa Sahin, MD, PhD Dr. Sahin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Regenxbio . Dr. Sahin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Centene. Dr. Sahin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Dr. Sahin has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for PTEN Research. Dr. Sahin has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Sahin has received research support from NIH. The institution of Dr. Sahin has received research support from Tuberous Sclerosis Alliance. The institution of Dr. Sahin has received research support from Charities Aid Foundation. The institution of Dr. Sahin has received research support from Simons Foundation Autism Research Initiative. The institution of Dr. Sahin has received research support from Aucta Pharmaceuticals . The institution of Dr. Sahin has received research support from Loulou Foundation.